A historic moment: WHO recommends deployment of a malaria vaccine finally developed after a 100-year endeavour. The WHO have advised that the RTS,S/AS01 vaccine, also known as Mosquirix, developed by GlaxoSmithKline (London, England) over the last 30 years in…
Phase III trials for the VLA1553 vaccine against chikungunya virus indicated promising results by inducing protective CHIKV neutralizing antibody titers…
Infection with dengue virus makes mosquitoes more sensitive to warmer temperatures, as does infection with the bacterium Wolbachia used to…
Scientists from Imperial College London (UK) and the Wellcome Sanger Institute (Cambridge, UK) have mapped the genetic changes malaria parasites…
New research using plankton has revealed that not all hosts are equal when it comes to infectious disease spread between…
Malara parasites showing artemisinin resistance previously seen in South-East Asia have recently emerged in areas of Rwanda in Sub-Saharan Africa. If the mutation causing resistance becomes prevalent across the continent it could have major public health impacts.
In this interview we speak to Jonathan Kurtis (Brown University, RI, USA) about the discovery of a parasite protein that provides new insights into how malaria regulates infection levels within its host, along with new possibilities for a broadly effective vaccine and a new class of antimalarial drugs.
The first clinical trial assessing two triple artemisinin-based combination therapies (TACTs) for treating malaria has suggested these are effective and present no safety concerns.
Upon investigating links between the risk of malaria in developing countries and the products demanded by consumers worldwide, researchers have estimated that a significant fraction of the malaria risk in deforestation hotspots is driven by the international trade of products.
In October 2019 researchers from Brazil identified a new parasite, which presented with similar symptoms to visceral leishmaniasis. To discover more about this novel parasite and other parasitic diseases in Brazil, we interviewed Sandra Maruyama from the Federal University of São Carlos (UFSCar; São Paulo, Brazil) about her research and the future of this field.
